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Abstract
Tankyrases (TNKS1 and TNKS2) are key regulators of cellular processes such as telomere pathway and Wnt signaling. IWRs
(inhibitors of Wnt response) have recently been identified as potent and selective inhibitors of tankyrases. However, it is not
clear how these IWRs interact with tankyrases. Here we report the crystal structure of the catalytic domain of human TNKS1
in complex with IWR2, which reveals a novel binding site for tankyrase inhibitors. The TNKS1/IWR2 complex provides a
molecular basis for their strong and specific interactions and suggests clues for further development of tankyrase inhibitors.
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Introduction
The two highly homologous human tankyrase isoforms,
TNKS1 and TNKS2, are members of the poly ADP-ribose
polymerase (PARP) family of 17 proteins that share a catalytic
PARP domain [1]. These PARP proteins cleave NAD+ (Figure 1)
into ADP-ribose and nicotinamide and transfer the ADP-ribose
units onto their substrates, resulting in a post-translational
modification referred to as PARsylation. Cellular functions of
many PARP proteins remain unknown.
PARP1 and PARP2, the two best characterized family members,
are key players in homologous recombination DNA damage
response and have been pursued as cancer targets for over a decade
[2]. A few PARP1/2 inhibitors such as (R)-2-(2-methylpyrrolidin-
2-yl)-1H-benzo[d]imidazole-4-carboxamide (ABT-888) and 4-(3-
(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)
phthalazin-1(2H)-one (AZD2281) (Figure 1) have shown prom-
ising results in clinical trials [3]. They contain functional groups
that resemble nicotinamide. Structural studies of PARP inhibitor
complexes reveal that these compounds are anchored in the
nicotinamide pocket in a very similar manner [4]. Using ABT-
888 as a representative example, the nicotinamide oxygen forms
hydrogen bonds with both the side chain hydroxyl of Ser470 and
the hydrogen NH of Gly429 in PARP2, while one of the
hydrogens on the primary amide forms a hydrogen bond with
the main chain oxygen of Gly429 in PARP2. In addition, the
imidazole of ABT-888 stacks with the side chain of Tyr472 of
PARP2.
Recently, tankyrases have gained increased attention as
potential drug targets. They were first discovered as factors that
regulate telomere homeostasis by modifying the negative regulator
of telomere length, TRF1 [5]. Tankyrases also mark axin, the
concentration-limiting component of the b-catenin destruction
complex, for degradation, and tankyrase inhibition antagonizes
the Wnt signal transduction pathway by stabilizing axin and
promoting b-catenin degradation [6]. Therefore, inhibition of
tankyrase activity appears to be a promising strategy for multiple
therapies in the treatment of cancer. So far, two different classes of
potent and selective small molecule tankyrase inhibitors, 4-
((3aR,4S,7R,7aS)-1,3-dioxo-3a,4,7,7a-tetrahydro-1H-4,7-metha-
noisoindol-2(3H)-yl)-N-(quinolin-8-yl)benzamide (IWR1) and 2-
(4-(trifluoromethyl)phenyl)-7,8-dihydro-3H-thiopyrano[4,3-d]pyr-
imidin-4(5H)-one (XAV939), have been identified [6,7]. IWR1
(1) inhibits TNKS1 and TNKS2 with IC50 of 131 nM and
56 nM, respectively, but does not inhibit PARP1 or PARP2 up to
a concentration of 18.75 mM[ 6 ] .X A V 9 3 9w a so r i g i n a l l y
developed as a PARP1/2 inhibitor, albeit a weak one with IC50
of 2.2 mM and 0.11 mM for PARP1 and PARP2, respectively,
and it was recently reported to be a more potent inhibitor of
TNKS1 and TNKS2 with IC50 of 11 nM and 4 nM, respectively
[6]. As expected, XAV939 binds to the nicotinamide pocket of
TNKS2 through interactions similar to those observed in other
PARP inhibitor complexes (Figure 1) [8], maintaining the three
aforementioned, conserved hydrogen bonds with a serine
hydroxyl, as well as the oxygen and NH from a glycine main
chain. In this TNKS2 structure, XAV939 cyclic amide behaves
as an isosteres for ABT-888’s primary amide. There is also a
stacking interaction between the pyrimidinone of XAV939 and
the Tyr1071 side chain of TNKS2. IWR compounds, however,
do not share these features for anchoring in the nicotinamide
pocket (Figure 1). It is not clear how these IWR compounds bind
to tankyrases and thus the structure-activity relationship for these
compounds has been difficult to interpret [9].
Herein, we report a high-resolution crystal structure of the
Human TNKS1 catalytic domain in complex with IWR2 (2) (PDB
code: 4DVI) and describe the structural basis for its potency and
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33740selectivity over PARP1 and PARP2. Our structure reveals a novel
binding mode for a tankyrase inhibitor and provides a clear
explanation for the reported structure-activity relationship of the
IWRs, and important clues for the further optimization of these
compounds.
Results and Discussion
The crystals of the TNKS1/2 complex diffracted to 1.9 A ˚ with
synchrotron radiation. There are two crystallographically inde-
pendent TNKS1/2 complexes in the crystal structure, highly
similar to each other (with a backbone rmsd of 0.6 A ˚). The
TNKS1/2 complex structure reveals that 2 does not bind to the
nicotinamide pocket but instead occupies a different pocket
(Figure 2A), which is not present in either apo or XAV939 bound
tankyrase structures (Figure 2B) [8,10]. It only becomes available
upon the binding of 2 and we thus refer to it as the induced pocket.
This induced pocket is created by the movement of Phe1188 of the
a3 helix and the D-loop, part of which is disordered in the present
crystal structure, away from one another. The binding of 2 to the
induced pocket of TNKS1 suggests that IWR compounds are
likely non-competitive inhibitors of tankyrases.
In the crystal structure, 2 adopts a conformation in which the
central phenyl is almost perpendicular to the norbornyl group and
rotated by about 60u away from the plane of the amide group
(Figure 2C). There are three hydrogen bonds between 2 and
TNKS1. One of the two carbonyl oxygens of the pyrrolidine dione
group is hydrogen bonded to the main chain NH of Tyr1213 and
the carbonyl oxygen of the amide group is hydrogen bonded to the
main chain NH of Asp1198. The CH at the 6-position of the
quinoline is also involved in a CH
…O=C hydrogen bonding
interaction with the main chain carbonyl oxygen of Gly1196.
Moreover, the quinoline group in 2 engages in hydrophobic
interaction with the side chain of Phe1188 and stacking interaction
with the side chain of His1201 of the D-loop. The quinoline group
is co-planar to the amide group as a result of the intra-molecular
hydrogen bond between the quinoline nitrogen and the amide
NH.
Structure-activity relationship studies carried out previously
with some of the analogs of 2 in a cellular luciferase-based reporter
assay can now be interpreted with the hydrogen bonding and
hydrophobic interactions identified from the TNKS1/2 crystal
structure (Figure 3) [9]. The methyl group at the 4 position of the
quinoline moiety of 2 does not enhance interaction with TNKS1
and it is not surprising that the reported inhibitory activity of the
des-methyl compound, 1, is similar to that observed for 2.
However, replacement of the quinoline group in 1 with 5,6,7,8
tetrahydroquinoline group (3) dramatically changes the confor-
mation and severely diminishes the activity and highlights the
importance of the above mentioned CH
…O=C interaction and
the stacking interaction with His1201. Deletion of the pyridine
moiety from the quinoline ring (4) also leads to loss of the stacking
interaction with His1201 and abolishes activity. A methoxy group,
on the other hand, is known to engage in or enhance the stacking
interaction with aromatic groups [11], thus the addition of 2-
methoxy substituent to 4 restores most of the activity (5). Quantum
mechanical calculations (Figure S1) indicate that introduction of a
methyl group to the 7 position of the quinoline does not distort the
co-planar conformation of the amide quinoline critical for stacking
against the His1201 side chain as much as the methylation of the
amide group. Consistent with this analysis, the methylated
quinoline analog (6) is only 4 fold less potent than 1 while the
N-methylated amide analog (7) does not have any measurable
activity up to a concentration of 25 mM. Similarly, the benzyl
amide analog (8) needs to adopt a strained conformation in order
to engage in a face-to-face stacking interaction with His1201
(Figure S1) and has, as a result, diminished activity. According to
quantum mechanical calculations, the saturation of the central
phenyl group in 1 does not alter the conformational preferences
significantly (Figure S1) and is likely to maintain the important
hydrogen bonding and stacking interactions between 1 and
TNKS1. There is only a slight loss in activity for the cyclohexyl
Figure 1. Chemical structures of NAD+, ABT-888, AZD2281, XAV939, IWR1, and IWR2 and the binding modes of ABT-888 and
XAV939 to PARP2 and TNKS2. The nicotinamide in NAD+ and the nicotinamide-mimic moieties in ABT-888, AZD2281, and XAV939 are
highlighted in red. ABT-888 and XAV939 bind to conserved serine and glycine residues of PARP2 and TNKS2 through three hydrogen bonds. These
serine and glycine residues as well as the hydrogen bonds are highlighted in blue.
doi:10.1371/journal.pone.0033740.g001
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piperidine group would make it energically much less favorable to
adopt the conformation observed in the crystal structure (Figure
S1). Consistent with our analysis, 10 is 25 fold less active than 9.I n
addition, the extension of the middle cyclohexyl group in 9 with an
extra methylene atom (11) is likely to disrupt the hydrogen
bonding interactions and results in significant loss of inhibitory
activity. Interestingly, the exo enantiomer of 1 (12) is 25 fold less
active than the endo enantiomer even though the structural
difference between the two enantiomers is very subtle: the spatial
swapping of the ethylene moiety with the methylene bridge head
converts the endo enantiomer to exo enantiomer. This suggests
that the partially positive hydrogen atoms of the ethylene group
may not be as well tolerated as the bridgehead methylene group in
the pocket created by Tyr1213, Tyr1224, and Ile1228 of TNKS1.
Inhibitors that bind to the induced pocket of tankyrases possess
advantages in terms of chemical space and selectivity. Since the
nicotinamide pocket has been well explored for designing PARP
inhibitors, it may be challenging to come up with new chemotypes
that bind to the nicotinamide pocket for the inhibition of
tankyrases. IWRs represent a new class of tankyrase inhibitors
that bind to the previously unknown induced pocket and it is likely
that other chemotypes may also bind to this induced pocket that
maintain the key binding interactions observed for 2. Residues
composing the nicotinamide pocket are highly conserved among
all PARP family members, presenting a major challenge for the
development of specific tankyrase inhibitors. The regulatory
helical domain of PARP1, PARP2, PARP3, and PARP4
immediately N-terminal to the catalytic domain could be used to
obtain some selectivity over these PARP proteins as in the case
with XAV939 which sterically clashes with the N-terminal helical
domain of PARP1, PARP2, PARP3, and PARP4 [8]. This N-
terminal helical domain, however, is not conserved in other PARP
proteins, making it very difficult to achieve broader selectivity
among the PARP family for tankyrase inhibitors. Residues
forming the induced pocket of tankyrases, on the other hand,
are much less conserved among other PARP family members
(Figure 4). For example, the critical His1201 from the D-loop of
TNKS1 (His1048 in TNKS2) is not conserved in other PARP
proteins; the a3 helix N-terminal to the D-loop is slightly shorter in
tankyrases due to the insertion of a proline (Pro1187) and deletion
of two amino acids, resulting in a narrower induced pocket.
Therefore, one is likely to achieve broader selectivity over PARP
family members with compounds that bind to the induced pocket.
For example, the selectivity of XAV939 for TNKS1 over PARP2
is only 10 fold whereas the selectivity of 2 is greater than 143 fold
[6].
The TNKS1/2 complex structure and molecular modeling
analysis suggest a number of distinct routes to further optimize
tankyrase inhibitors that bind to the induced pocket. Preliminary
metabolic stability studies indicated enzymatic cleavage of the
amide bond to be the primary clearance mechanism for IWRs [9].
It is clear from our crystal structure that the amide quinoline of 2
can be replaced by other more stable moieties that maintain the
same hydrogen bonding and stacking interactions. Modifications
Figure 2. Crystal Structure of the TNKS1/IWR2 complex. (A)
Surface representation of TNKS1 (colored in wheat) with IWR2 (colored
in green) bound. XAV939 (colored in yellow) from the crystal structure
of TNKS2/XAV939 is superimposed to illustrate that IWR2 binds to a
different pocket other than the nicotinamide pocket. (B) Superposition
of crystal structures of TNKS1/IWR2 (colored in wheat and green) and
apo TNKS1 (colored in cyan), with residues Phe1188 and His1201 in
sticks, to illustrate the opening of the induced pocket in TNKS1 upon
IWR2 binding. IWR2 binds to TNKS1 through three highlighted
hydrogen bonds. (C) The induced pocket, showing the hydrogen bond
and hydrophobic interactions between IWR2 and TNKS1 residues,
colored as in (A).
doi:10.1371/journal.pone.0033740.g002
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doi:10.1371/journal.pone.0033740.g003
Figure 4. Structure based sequence alignment of TNKS1, TNKS2, and other PARP family members. Key residues Pro1187 (following
deletion of two amino acids) and His1201 of the induced pocket in TNKS1 are highlighted, together with their equivalent residues in other PARP
proteins, to illustrate the poor conservation of these amino acids.
doi:10.1371/journal.pone.0033740.g004
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more favorable binding geometries. Quantum mechanical calcu-
lations suggest that the ,60u dihedral between the phenyl and
amide observed in the crystal structure of 2 results in an intrinsic
reduction of potency by approximately 25-fold (,2 kcal/mol).
The pyrrolidine dione group also does not appear optimal for
tankyrase binding. One of the two carbonyl oxygens is not
involved in hydrogen bonding or any other interaction with the
protein and thus could be replaced. In addition, it is also
conceivable that the norbornyl group does not interact optimally
with the Tyr1213, Tyr1224, and Ile1228 of TNKS1. Further-
more, since the induced pocket is adjacent to the nicotinamide
pocket which is unoccupied and unhindered, it may be possible to
extend the induced pocket binding tankyrase inhibitors such as 2
into the nicotinamide pocket to gain additional interactions,
resulting in even greater potency while maintaining good
selectivity due to the specificity of the induced pocket.
IWR compounds may have activity for proteins other than
PARP family members; thus, minimizing potential side effects
from the off-target interactions is essential for further development
of tankyrase inhibitors derived from IWRs. Future studies such as
chemical proteomics screens need to be carried out to identify
potential unintended targets of these inhibitors.
We note that induced pockets have been observed for other
enzymes such as protein kinases. An allosteric binding pocket was
reported for a diaryl urea class of highly potent and selective
inhibitors against human p38 MAP kinase and the formation of
this pocket requires a large conformation change [12]. Improving
interactions in this allosteric pocket and establishing additional
interactions in the adjacent ATP pocket enhanced the affinity of
the inhibitors by 12,000 fold [12]. Imatinib, developed to treat
chronic myelogenous leukemia (CML) and gastrointestinal stromal
tumor (GIST), binds to similar sites in the human Abl and Kit
kinases and shows excellent efficacy and specificity for Abl and Kit
[13,14]. Interestingly, imatinib was found to inhibit strongly
(IC50=80 nM) a non-kinase target, the oxidoreductase NQO2,
from a screen carried out to identify off-target proteins [15].
Vemurafenib, developed for the treatment of metastatic melano-
ma caused by the BRAFV600E mutation, also binds to an induced
pocket created by an outward shift of the aC helix [16].
In summary, the present structure reveals a novel binding mode
for tankyrase inhibitors and, in conjunction with molecular
modeling analysis, provides insights into the molecular basis for
the key interactions between IWRs and tankyrases. In addition, it
explains the structure activity relationship of the IWRs and will be
important for further optimization of tankyrase inhibitors.
Materials and Methods
Human TNKS1 (1104–1314) with a C-terminal His6 tag was
cloned into the PET28a vector and expressed in E. Coli Rosetta
(DE3). The culture was grown in TB media at 37uC until OD600
reached ,2. The culture was then cooled to 18uC and induced by
addition of 0.5 mM IPTG. Expression was allowed to continue
overnight and cells were harvested by centrifugation. The resulting
cell pellet was resuspended in lysis buffer (25 mM Hepes, 300 mM
NaCl, 2.5 mM BME, pH 8.0) supplemented with 0.8% Protease
Inhibitor Cocktail (Sigma). The cells were lysed by Microfluidizer
(Microfluidics) and cell debris was removed by centrifugation
(190006 g, 90 min, 4uC). The supernatant was incubated with
Talon Metal Affinity resin (Clontech) overnight at 4uC before
loaded onto a column. The Co++ Talon resin was washed with a
lysis buffer containing 5 mM Imidazole. TNKS1His6 was then
eluted with a lysis buffer containing 60 mM Imidazole. The
TNKS1His6 protein was further purified in gel filtration buffer
(25 mM Hepes, 200 mM NaCl, 14 mM BME, 5% glycerol,
pH 8.0) by size exclusion chromatography using Superdex 200
(GE Healthcare).
The TNKS1/IWR2 complex was obtained by incubating
TNKS1His6 at 10 mg/ml with IWR2 (commercially available
from AKos) in 2-fold molar excess for 30 minutes at 4uC. Crystals
of TNKS1/IWR2 were obtained at 4uC in hanging drops by
mixing 0.5 mL of TNKS1/IWR2 complex with 0.5 mL of well
solution containing 100 mM MES pH 6.0, 0.2 M or 0.4 M Di-
Ammonium Tartrate, 12.5–25% PEG3350. Plate shaped crystals
appeared overnight and grew to maximum size in a few days.
These crystals belong to the spacegroup P212121 with unit cell
parameters of a=41.47, b=77.94, c=146.54 A ˚. Paratone-N
mineral oil was used as cryo protectant and diffraction data were
collected on beamline 5.0.1 at the Advanced Light Source (ALS),
Berkeley, CA and processed with HKL2000. The TNKS1/IWR2
complex structure was solved by molecular replacement with
AMoRe using the apo TNKS1 structure (2RF5) as the template.
Model building was carried out with QUANTA and refinement
was done using CNX. Details on data processing and refinement
statistics are given in Table S1.
Supporting Information
Figure S1 Quantum mechanical calculations were done
at the B3LYP/6-31G(d) level of theory using the software
package Gaussian 03. The dihedral energy scan calculations
for the dihedrals highlighted were performed with 10 degree
increments for the scanned dihedral and all the other dihedrals,
angles and distances were allowed to relax during the calculations.
Single point solvation energies were computed for the final
geometries at the same level of theory using the CPCM solvation
method and the UAKS cavity model. In each case, the rotated
dihedral is highlighted.
(DOC)
Table S1 Data Collection and refinement statistics for
TNKS1/IWR2 structure.
(DOC)
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